Morningstar Fund Report  | 01/04/2025Print

AXA Framlington Biotech Fund - R Income

Performance History28/02/2025
Growth of 1,000 (GBP) Advanced Graph
AXA Framlington Biotech Fund - R Income
Fund2.33.01.10.20.6
+/-Cat11.410.92.43.1-0.7
+/-B’mrk2.00.6-6.26.8-3.4
 
Category: Sector Equity Biotechnology
Category Benchmark: Morningstar Gbl Biotechnolo...
Key Stats
NAV
31/03/2025		 GBX 240.30
Day Change -1.44%
Morningstar Category™ Sector Equity Biotechnology
IA (formerly IMA) Sector Specialist
ISIN GB0031007254
Fund Size (Mil)
31/10/2024		 GBP 403.40
Share Class Size (Mil)
31/03/2025		 GBP 19.61
Max Initial Charge -
Ongoing Charge
12/02/2025		  1.57%
Investment Objective: AXA Framlington Biotech Fund - R Income
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.
Returns
Trailing Returns (GBP)31/03/2025
YTD-7.40
3 Years Annualised1.98
5 Years Annualised5.36
10 Years Annualised3.06
12 Month Yield 0.00
Management
Manager Name
Start Date
Chris Eccles
29/03/2024
Cinney Zhang
29/03/2024
Click here to see others
Inception Date
26/11/2001

Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDMorningstar Gbl Biotechnology NR USD
Portfolio Profile for  AXA Framlington Biotech Fund - R Income31/01/2025
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock99.230.0099.23
Bond0.000.000.00
Property0.000.000.00
Cash0.880.110.77
Other0.000.000.00
Top 5 Regions%
United States75.51
United Kingdom11.07
Europe - ex Euro6.42
Eurozone3.53
Asia - Emerging1.94
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
Vertex Pharmaceuticals IncHealthcareHealthcare7.93
Amgen IncHealthcareHealthcare6.55
Regeneron Pharmaceuticals IncHealthcareHealthcare6.26
AstraZeneca PLC ADRHealthcareHealthcare6.15
Alnylam Pharmaceuticals IncHealthcareHealthcare4.16
Increase Decrease New since last portfolio
AXA Framlington Biotech Fund - R Income
Growth Of 1000 (GBP) 28/02/2025
Fund:  AXA Framlington Biotech Fund - R Income
Category:  Sector Equity Biotechnology
Category Index:  Morningstar Gbl Biotechnology NR USD
Growth of 1,000 GBP
Annual Returns (GBP)28/02/2025
 201820192020202120222023202428/02
Price Return-7.3418.1531.422.353.021.090.190.62
+/- Category0.62-2.055.4511.3810.852.373.11-0.65
+/- Category Index-5.491.44-1.512.050.55-6.246.77-3.40
% Rank in Category5762201626314659
Trailing Returns (GBP)31/03/2025
   Total Returns   +/- Category   +/- Category Index
1 Day-1.44   -1.52-0.80
1 Week-4.42   -2.51-1.83
1 Month-7.97   -3.05-2.95
3 Months-7.40   -1.96-5.87
6 Months-10.64   -5.353.06
YTD-7.40   -2.86-5.91
1 Year-11.07   -3.134.09
3 Years Annualised1.98   0.70-1.85
5 Years Annualised5.36   0.48-1.68
10 Years Annualised3.06   -1.31-2.81
 
Category: Sector Equity Biotechnology
Category Index: Morningstar Gbl Biotechnology NR USD
Quarterly Returns (GBP)28/02/2025
 Quarter 1Quarter 2Quarter 3Quarter 4
20244.322.33-2.75-3.50
2023-4.18-1.220.006.80
2022-8.89-0.2615.71-2.03
2021-6.467.795.06-3.38
20200.1128.96-2.564.47
 
 
 
Morningstar Rating™(Relative to Category)28/02/2025
 Morningstar ReturnMorningstar RiskMorningstar Rating™
3-YearAbove AverageAverage4 star
5-YearAbove AverageAverage5 star
10-YearAverageAverage3 star
OverallAbove AverageAverage4 star
 
Category :  Sector Equity BiotechnologyClick here to see our Methodology
Volatility Measurements28/02/2025
 
3-Yr Std Dev16.28 %
3-Yr Mean Return8.59 %
 
3-Yr Sharpe Ratio0.27
 
Modern Portfolio Statistics28/02/202528/02/2025
 Standard IndexBest Fit Index
 Morningstar Gbl Biotechnology NR USD  Morningstar Gbl Biotechnology NR USD
3-Yr Beta0.770.77
3-Yr Alpha-0.03-0.03
 
Investment Style Details31/01/2025
Morningstar Style Box®
Equity Style
SizeRel to Cat
Average Mkt Cap (Mil)GBP 15419-
Market Capitalisation% of Equity
Giant11.77
Large26.68
Medium30.58
Small14.41
Micro16.56
Valuations and Growth RatesEquity PortfolioRelative to Category
Price/Prospective Earnings17.420.96
Price/Book3.400.97
Price/Sales6.141.17
Price/Cash Flow13.630.79
Dividend-Yield Factor0.591.65
 
Long-Term Projected Earnings Growth8.400.55
Historical Earnings Growth-9.650.80
Sales Growth5.670.88
Cash-Flow Growth-15.051.39
Book-Value Growth8.901.19
 
Category: Sector Equity Biotechnology
Asset Allocation31/01/2025
Asset Allocation
 % Long% Short% Net Assets
Stock99.230.0099.23
Bond0.000.000.00
Property0.000.000.00
Cash0.880.110.77
Other0.000.000.00
World Regions31/01/2025
 % of EquityRelative to Category
United States75.510.92
Canada1.541.23
Latin America0.000.00
United Kingdom11.072.99
Eurozone3.530.81
Europe - ex Euro6.421.10
Europe - Emerging0.00-
Africa0.00-
Middle East0.000.00
Japan0.000.00
Australasia0.000.00
Asia - Developed0.000.00
Asia - Emerging1.941.37
 
Category: Sector Equity Biotechnology
Sector Weightings31/01/2025
 % of EquityRelative to Category
HealthcareHealthcare100.001.00
 
Category: Sector Equity Biotechnology
Top 10 Holdings31/01/2025
 Portfolio NEW
Total Number of Equity Holdings53
Total Number of Bond Holdings0
Assets in Top 10 Holdings48.77
NameSectorCountry% of Assets
Vertex Pharmaceuticals Inc206United States7.93
Amgen Inc206United States6.55
Regeneron Pharmaceuticals Inc206United States6.26
AstraZeneca PLC ADR206United Kingdom6.15
Alnylam Pharmaceuticals Inc206United States4.16
Gilead Sciences Inc206United States4.16
argenx SE ADR206United States3.94
Neurocrine Biosciences Inc206United States3.57
Insmed Inc206United States3.47
United Therapeutics Corp206United States2.59
 
Increase Decrease New since last portfolio
Category: Sector Equity Biotechnology
 
Management
Name of CompanyAXA Investment Managers UK Ltd
Phone44 20 7003 2345
Websitewww.axa-im.com
Address22 Bishopsgate
 London   EC2N 4BQ
 United Kingdom
DomicileUnited Kingdom
Legal StructureUnit Trust
UCITSYes
Inception Date26/11/2001
Fund Advisor(s)
AXA Investment Managers UK Ltd
Fund ManagerChris Eccles
Manager Start Date29/03/2024
Career Start Year2011
Education
University of Oxford, M.A.
 
Biography
Chris Eccles is a research analyst who specialises in testing and regulatory affairs. He researches stocks globally and focuses on the Healthcare sector. Chris joined Impax in March 2019. He started working in the financial industry in 2011 as a research analyst at Morgan Stanley where he focused on European large-cap pharmaceuticals. In 2014, he became a partner at the hedge fund Kola Capital where he worked as a global equities analyst for three years before moving to Stifel in 2017 to work as a Healthcare Specialist. Chris achieved an MA (Oxon) Physiological Sciences First Class Honours, from the University of Oxford.
Fund ManagerCinney Zhang
Manager Start Date29/03/2024
Fund ManagerCatherine Tennyson
Manager Start Date29/03/2024
Fees and Expenses
Sales Charges (Maximum) 
Max Initial Chargen/a
Max Exit Charge*n/a
Annual Charges
Max Annual Management Charge1.50%
Ongoing Charge1.57%
Purchase Details
Minimum Investments
Initial1000  GBP
Additional100  GBP
Savings50  GBP
Tax Free Savings Schemes
ISAsYes